Initial results in RRMM with modakafusp alfa: a first-in-class CD38-targeted immunocytokine

Modakafusp alfa is a first-in-class antibody–cytokine fusion protein (immunocytokine) consisting of two...

First-in-human study of REGN5458, a novel BCMA bispecific antibody

This article summarizes the updated safety, overall response, and response durability in patients treated in the phase I...

Cevostamab for relapsed/refractory multiple myeloma

Cevostamab targets the membrane-proximal domain of Fc receptor homolog 5 (FcRH5), which is expressed exclusively on B-lineage cells. Cevostamab, as...

FDA approves ciltacabtagene autoleucel for the treatment of patients with RRMM

On February 28, 2022, it was announced that the U.S. Food and Drug Administration (FDA) granted the approval of...

In the era of upfront quadruplets, is there still a role for allogeneic transplant?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple...

Novel risk score for predicting early relapse in patients with multiple myeloma

Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis,...

Challenges and future directions for access to cell therapies: A global perspective

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), a joint session...

What factors correlate with a better response to BCMA-directed CAR T-cell products?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple...

What factors correlate with a better response to BCMA-directed CAR T-cell products?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple...

The EMA CHMP provide positive opinion on cilta-cel for RRMM

On March 24, 2022, it was announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) provide...

Management of short-, medium-, and long-term complications in patients receiving CAR T-cell therapy

Complications can arise at any time after the administration of CAR T-cell therapy; however, with...

Access and future prospects of advanced immunotherapies for multiple myeloma in Europe

During the 4th European CAR T-cell Meeting, the Multiple Myeloma Hub was pleased to speak with Michel Delforge,...

How do CAR T-cell recipients respond to COVID-19 vaccination?

During the 4th European CAR T-Cell Meeting, the Multiple Myeloma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv,...

EMN recommendations for COVID-19 vaccination in patients with MM

Multiple myeloma (MM) and other monoclonal gammopathies can increase patient susceptibility to infection, either as a direct result of...

Humoral and cellular responses in patients with lymphoid malignancies receiving SARS-Cov-2 vaccination

Factors that influence the efficacy of Severe Acute Respiratory Syndrome Coronavirus-2...

COVID-19 lessons learnt in patients with multiple myeloma

During the 18th International Myeloma Workshop, Evangelos Terpos provided a summary of what has been learnt with respect to patients with...